Covista (CVSA) Earnings: Q1 Fiscal 2027 Results and Next Report Date

The quarter ended September 30, 2026 and Covista published the results on October 29, 2026. Revenue and diluted EPS are shown against Q1 fiscal 2026, the same quarter a year earlier, which takes seasonal swings out of the comparison. Covista reports EPS two ways: GAAP, under the accounting rules every US filer follows, and adjusted, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Covista was formerly Adtalem Global Education (ticker ATGE). Its fiscal year ends June 30, so Q1 fiscal 2027 is the quarter ended September 30, 2026.
• Diluted EPS on this page is total diluted EPS, including discontinued operations (litigation costs and settlements from prior divestitures). Diluted EPS from continuing operations was $2.07, against $1.65 a year earlier.

Source: Covista Q1 fiscal 2027 results, October 29, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Covista splits revenue in its own release, under its own labels, for Q1 fiscal 2027 against Q1 fiscal 2026. Indented lines are parts of the line above them.

• Covista's Chamberlain revenue was $192 million in Q1 fiscal 2027, up 7% from $179 million in Q1 fiscal 2026, 38% of total revenue.
• Covista's Walden revenue was $217 million in Q1 fiscal 2027, up 14% from $190 million in Q1 fiscal 2026, 42% of total revenue.
• Covista's Medical and Veterinary revenue was $103 million in Q1 fiscal 2027, up 10% from $93.1 million in Q1 fiscal 2026, 20% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q1 fiscal 2027 release, Covista said:

“Covista raised its revenue guidance for fiscal year 2027 from a range of $2,050 million to $2,090 million, or approximately 5% to 7% growth year-over-year, to a range of $2,060 million to $2,095 million, or approximately 5.5% to 7% growth year-over-year.”

“Covista also raised its adjusted earnings per share guidance from a range of $8.90 to $9.15, or approximately 8% to 11% growth year-over-year, to a range of $9.00 to $9.20, or approximately 9% to 11.5% growth year-over-year.”

Source: Covista Q1 fiscal 2027 release, Oct 29, 2026.

This is the company's own guidance as of Oct 29, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the CVSA forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

Revenue and total diluted EPS (including discontinued operations), each as first reported in that quarter's release. Releases before the rename were issued as Adtalem Global Education. Q3 fiscal 2026 total diluted EPS of $1.20 included a loss from discontinued operations; diluted EPS from continuing operations that quarter was $1.67.

Covista's next report is expected around January 28, 2027, a date estimated from its reporting history that the company has not yet confirmed. This page will show Q1 fiscal 2027 until those results are out and have been checked against the release.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q1 fiscal 2027 (this page), reported Oct 29, 2026

Covista, formerly Adtalem Global Education, earns tuition and fees from five accredited institutions, reported in three segments. In Q1 fiscal 2027 Walden brought in $216.7 million, Chamberlain $192.4 million and Medical and Veterinary $102.5 million, for total revenue of $511.5 million, up 10.7%. (Covista Q1 fiscal 2027 release, Oct 29, 2026; Covista Form 10-K, fiscal 2026, Aug 6, 2026)

Enrollment drives the revenue line. Total student enrollment was 104,713, up 7.6% and the 13th straight quarter of growth. Walden enrollment rose 12.8% to 58,881, its highest in university history, and Walden revenue rose 14.1% on enrollment and higher tuition rates. Chamberlain enrollment rose 1.3% to 40,351 and revenue 7.4%, on higher enrollment, average student courseload and tuition rates. (Covista Q1 fiscal 2027 release, Oct 29, 2026; Covista Form 10-Q, Q1 fiscal 2027, Oct 29, 2026)

Chamberlain's growth is in pre-licensure nursing: pre-licensure BSN enrollment grew for a 17th straight quarter, while enrollment in post-licensure nursing programs has declined, according to the 10-Q. Medical and Veterinary, which covers the American University of the Caribbean, Ross Medicine and Ross Veterinary schools, grew enrollment 3.5% to 5,481 and revenue 10.0% to $102.5 million. (Covista Q1 fiscal 2027 release, Oct 29, 2026; Covista Form 10-Q, Q1 fiscal 2027, Oct 29, 2026)

Most of the money comes from federal student aid. Covista's Title IV institutions collectively receive 78% of their revenue from Title IV programs; under the 90/10 Rule an institution that gets more than 90% of its cash revenue from federal education assistance in two consecutive fiscal years loses Title IV eligibility. Audited fiscal 2025 rates ranged from 70% at Chamberlain to 86% at the two medical schools. (Covista Form 10-K, fiscal 2026, Aug 6, 2026)

Covista's total diluted EPS was $1.95 in Q1 fiscal 2027 and adjusted EPS $2.19, up 25.1% from $1.75. Income from continuing operations was $71.5 million, or $2.07 per diluted share; a $4.1 million loss from discontinued operations, tied to litigation costs and settlements from prior divestitures, took $0.12 off total EPS. (Covista Q1 fiscal 2027 release, Oct 29, 2026)

Adjusted EPS also adds back $0.18 of strategic advisory costs ($6.2 million), $0.04 of amortization of acquired intangible assets and $0.02 of debt modification costs, and subtracts $0.06 for a U.S. tax benefit from an increase in foreign-derived income and $0.06 for the tax impact of the adjustments. (Covista Q1 fiscal 2027 release, Oct 29, 2026)

Buybacks cut the share count. Diluted shares were 34,573 thousand, against 37,057 thousand a year earlier. Covista repurchased $84 million of shares in the quarter, 658,088 shares at an average cost of $127.63, and repaid $163.0 million of long-term debt, leaving $510.0 million of Term Loan B principal and net leverage of 0.5x. (Covista Q1 fiscal 2027 release, Oct 29, 2026; Covista Form 10-Q, Q1 fiscal 2027, Oct 29, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Covista gives full-year revenue and adjusted EPS guidance in its release. With Q1 fiscal 2027 results it raised fiscal 2027 revenue guidance to $2,060 million to $2,095 million, about 5.5% to 7% growth, from $2,050 million to $2,090 million, and adjusted EPS guidance to $9.00 to $9.20, about 9% to 11.5% growth, from $8.90 to $9.15. It does not provide a reconciliation of the non-GAAP guidance to GAAP. (Covista Q1 fiscal 2027 release, Oct 29, 2026)

Covista also said Chief Financial Officer Robert Phelan plans to retire and will stay in the role until a successor is named. (Covista Q1 fiscal 2027 release, Oct 29, 2026)

A consensus figure is the average of the models published by the analysts who cover Covista, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Covista's own release and filings put weight on for Q1 fiscal 2027, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning CVSA is on is CVSA a buy or a sell?, what analysts expect next is on the CVSA forecast, and what the company does is on the Covista (CVSA) stock page.

Every number on this page can be traced to a document Covista published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.